Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

BroadOak Capital Partners

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 24
Average round size
info
The average size of a deal this fund participated in
$11M
Portfolio companies 20
Rounds per year 1.33
Lead investments 6
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.17
Exits 3
Key employees 5

Areas of investment

  • Biotechnology
  • Health Care
  • Genetics
  • Life Science
  • Pharmaceutical
Summary

BroadOak Capital Partners appeared to be the VC, which was created in 2006. The main office of represented VC is situated in the Bethesda. The venture was found in North America in United States.

The standard case for the fund is to invest in rounds with 2 partakers. Despite the BroadOak Capital Partners, startups are often financed by Ben Franklin Technology Partners of Southeastern Pennsylvania, Z80 Labs Technology Incubator, Rand Capital. The meaningful sponsors for the fund in investment in the same round are Research Corporation Technologies, Oxford Finance LLC, Northpond Ventures. In the next rounds fund is usually obtained by Brooks Automation.

Among the most successful fund investment fields, there are Life Science, Pharmaceutical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Empire Genomics, Rubicon Genomics, Halo Labs.

The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 42 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2016. The fund is generally included in less than 2 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BroadOak Capital Partners:
Typical Co-investors
BroadOak Capital Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BroadOak Capital Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
2U Consulting Bayern, Germany, Nuremberg
Dauphin Capital Partners New York, New York, United States
Dongrong Ziben China, Ningbo, Zhejiang
Drive by DraftKings Boston, Massachusetts, United States
East Midlands Business Angels Newark Upon Trent, Nottinghamshire, United Kingdom
Global Atlantic Atlanta, Georgia, United States
Hypersphere Ventures -
Insight China, Shanghai
Kokuyo Japan, Osaka, Osaka Prefecture
Kyoto Chuo Shinkin Bank Japan, Kyoto, Kyoto Prefecture
Leadiant Biosciences Gaithersburg, Maryland, United States
Magellan Health Services Avon, Connecticut, United States
Melo7 Tech Partners New York, New York, United States
Moxxie Ventures California, San Francisco, United States
Redbrick British Columbia, Canada, Victoria
Ridgebox Astoria, New York, United States
Spartech Ventures Dubai, United Arab Emirates
SteelBridge Laboratories Pennsylvania, Pittsburgh, United States
TIBCORP Central, Central Region, Singapore
Wit Capital New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

S2 Genomics

Biotechnology
Health Care
$16M23 Jan 2024 California, United States

Halo Labs

Analytics
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
$7M11 Jul 2022 Philadelphia, Pennsylvania, United States

seqWell

Biotechnology
Life Science
$7M29 Mar 2022 Beverly, Massachusetts, United States

Genomenon

Developer Tools
Enterprise Software
Genetics
Medical
Software
$20M08 Mar 2022 Ann Arbor, Michigan, United States

Genomenon

Developer Tools
Enterprise Software
Genetics
Medical
Software
$5M16 Mar 2021 Ann Arbor, Michigan, United States

Halo Labs

Analytics
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
$12M06 Apr 2020 Philadelphia, Pennsylvania, United States

seqWell

Biotechnology
Life Science
$9M14 Jan 2020 Beverly, Massachusetts, United States

InFuse Holdings

Health Care
Health Diagnostics
Hospital
$8M06 Nov 2019 Bethesda, Maryland, United States

Codex DNA

Advanced Materials
Biotechnology
Chemical
Genetics
Life Science
$25M09 Sep 2019 San Diego, California, United States
News
PBS Biotech Raises $10M in Funding

– PBS Biotech from Camarillo, CA is a manufacturer of single-use bioreactor systems.
– The company closed a $10M funding round.
– The investment was led by BroadOak Capital Partners.
– The new investment will be used to expand and industrialize the company’s portfolio of single-use bioreactor systems and contract process development services.

KromaTiD Receives $2.0 Million of Growth Capital Investment from BroadOak Capital Partners

BroadOak Capital Partners has invested in KromaTiD.
– KromaTiD’s sales and operations are rapidly accelerating, driven by growing market adoption of their products and services, such as the recently launched dGH In-Site™ and dGH SCREEN™ products for gene editing and gene therapy applications.
– This capital will be used to accelerate commercialization, support ongoing product development, and to increase capacity to meet growing demand.
– KromaTiD’s directional Genomic Hybridization™, or dGH™, today provides the genomic structural context necessary to optimize gene editing strategies for research and clinical purposes, such as therapeutic gene editing based on CRISPR technologies, requiring measurements that can only be made with a single cell, genome-wide analysis provided by dGH™.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BroadOak Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 24
Average round size 11M
Rounds per year 1.33
Peak activity year 2021
Lead investments 6
Follow on index 0.17
Exits 3
Group Appearance index 0.54

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

S2 Genomics

Biotechnology
Health Care
$16M23 Jan 2024 California, United States

Halo Labs

Analytics
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
$7M11 Jul 2022 Philadelphia, Pennsylvania, United States

seqWell

Biotechnology
Life Science
$7M29 Mar 2022 Beverly, Massachusetts, United States

Genomenon

Developer Tools
Enterprise Software
Genetics
Medical
Software
$20M08 Mar 2022 Ann Arbor, Michigan, United States

Genomenon

Developer Tools
Enterprise Software
Genetics
Medical
Software
$5M16 Mar 2021 Ann Arbor, Michigan, United States

Halo Labs

Analytics
Biopharma
Biotechnology
Health Diagnostics
Pharmaceutical
$12M06 Apr 2020 Philadelphia, Pennsylvania, United States

seqWell

Biotechnology
Life Science
$9M14 Jan 2020 Beverly, Massachusetts, United States

InFuse Holdings

Health Care
Health Diagnostics
Hospital
$8M06 Nov 2019 Bethesda, Maryland, United States

Codex DNA

Advanced Materials
Biotechnology
Chemical
Genetics
Life Science
$25M09 Sep 2019 San Diego, California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: